Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Structural guidance for malaria and TB

The Structural Genomics Consortium is spearheading the three-year Structure-guided Drug Discovery Consortium, which aims to bring pharma-quality medicinal chemistry capabilities to targets against malaria and tuberculosis. With a 3-year, $5 million grant from the Bill & Melinda Gates Foundation and another $10 million in supporting funds already available to its members, the drug discovery consortium will focus on projects that put early stage therapeutic assets in the hands of its key product development partners-Medicines for Malaria Venture

and the Global Alliance for TB Drug Development.

Data generated under the new consortium also will be made publicly accessible to the broader scientific community.

"After AIDS,

Read the full 1031 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers